Columnist Barth Keck takes a look at the words of the year chosen by various dictionary publishers, and offers one of his own.

We flew into St. Barth's airport knowing it would be different. The approach is steep and everything happens fast. Every second requires focus and precision. The runway feels extremely close by the ...

The National Organization for Rare Disorders (NORD(R)) today urged Congress to reauthorize the Rare Pediatric Disease Priority Review Voucher (RPD PRV) program by year-end, warning that continued ...

FORZINITY™ is a mitochondrial cardiolipin binder developed by Stealth BioTherapeutics for the treatment of Barth syndrome. FORZINITY (elamipretide HCl) is indicated for the improvement of muscle ...

Multiple key factors drive the expansion of the Barth syndrome therapeutics market. Firstly, growing awareness of Barth syndrome (a rare genetic disorder) has helped refine the diagnosis and increase ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Barth syndrome (BTHS) is a rare X-linked ...

NEEDHAM, Mass., Oct. 9, 2025 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a commercial-stage biotechnology company focused on the discovery, development and ...

After months of fighting, a Colorado family is breathing a sigh of relief after the FDA announced initial approval of an experimental medication helping to keep their son alive. "Like last night, I ...

Stealth BioTherapeutics Inc., a commercial-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, ...

After a rocky regulatory pathway filled with delays and a previous rejection, the US Food and Drug Administration (FDA) has approved Stealth BioTherapeutics’ Forzinity (elamipretide HCl) for the ...

After a long regulatory road that included a complete response letter in May, Stealth Biotherapeutics Inc. finally got its Barth syndrome drug across the finish line, with the U.S. FDA granting ...